The Neuroendocrine Tumor Research Foundation (NETRF) has awarded six new research grants totaling $1.85 million, approximately $1.5 million of which relates to nuclear medicine/radiology research.
The goal of the grant program is to support clinical, translational, and basic research for improving current treatments for neuroendocrine tumors (NETs) in academic centers in the U.S., Australia, Switzerland, and the U.K., the foundation said. NETs are uncommon and poorly understood cancers that occur in the body's hormone-producing cells.
The nuclear medicine and radiology grant projects include the following:
- A four-year project conducted by Dr. Rodney Hicks of the University of Melbourne that will include both laboratory tests and clinical trials aimed at improving the clinical benefits of peptide receptor radionuclide therapy (PRRT)
- A two-year project conducted by Roger Schibli, PhD, of the Paul Scherrer Institut in Zurich that will explore the safety of a novel radionuclide for more effective treatment of NETs
"We are funding projects with the potential to be rapidly transitioned from bench to clinic because time is critical to patients with these rare and advancing cancers," said NETRF CEO Elyse Gellerman in a statement.
